Patent 11889821 was granted and assigned to Trianni, Inc. on February, 2024 by the United States Patent and Trademark Office.
The invention provides compositions and methods for enhanced production of immunoglobulin diversity. Specifically, the invention provides compositions and methods for making accessible a B cell receptor repertoire that has not been culled by developmental tolerance mechanisms. The invention also provides transgenic animals, cells, and antibodies resulting from these compositions and methods.